Covid19, Corona Virus Infection, SARS (Severe Acute Respiratory Syndrome), SARS-CoV Infection
Conditions
Keywords
Covid19, Children, Adolescents
Brief summary
This is a protocol aimed at children and adolescents contaminated with COVID, treated at the Hospital das Clínicas, University of Sao Paulo, Brazil (HCFMUSP), in the recovery phase. The study aims to evaluate the spectrum of pathogenic lesions of the virus not only in the respiratory system, but digestive, immunological, neurological and others. Clinical, evolutionary, laboratory and functional parameters will be used.
Detailed description
School-age children and adolescents COVID-19 survivors may have persistent inflammation, a chronic course of COVID-19, with isolated or concomitant aggressions of various organs and systems, making this disease a potential chronic condition, impacting aspects of quality of life related to health (HRQoL), physical and mental health. In addition, pediatric COVID-19 can induce autoimmunity (with the possibility of primary hypothyroidism and type I diabetes mellitus), delayed linear growth and delayed pubertal development, secondary immunodeficiency and present genetic polymorphisms in brain plasticity impacting rehabilitation. School-aged children and adolescents with COVID-19 could present muscle weakness, dysautonomy, asthenia and physical inactivity, so it is essential that safe and effective interventions are developed to maintain adequate levels of physical activity and that they can be implemented on a large scale. However, to date, there are no systematic longitudinal studies that have evaluated all these aspects in a pediatric population that survived COVID-19, particularly with chronic conditions and who were hospitalized in a tertiary service.
Interventions
BEHAVIORALHome-based exercise training
Online strength and aerobic home-based exercise training, 3 times per week, for 12 weeks. The exercise program is composed by 2 intensity-levels (starter and advanced).
Sponsors
Hospital das Clínicas da Faculdade de Medicina da USP
Fundação de Amparo à Pesquisa do Estado de São Paulo
University of Sao Paulo
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
7 Years to 18 Years
Healthy volunteers
No
Inclusion criteria
* school-age children and adolescents diagnosed with COVID-19
Exclusion criteria
* school-age children and adolescents with MIS-C, who present: myocardial dysfunction, refractory cardiac arrhythmias, coronary artery aneurysms with or without thrombi, electrocardiographic alterations suggestive of myocardial infarction or ischemia and clinical signs of heart failure; * presence of any limitation or physical disability that prevents the practice of exercise; * pregnancy.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Quality of Life assessed by the Pediatric Quality of Life Inventory (Peds-QoL) | Change from Baseline at 3 months | The instrument was translated and validated for the Brazilian population |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Endothelial function will be assessed using a Doppler Ultrasound | Baseline, 3 months, 6 months, 12 months | Flow-mediated vasodilation (VMF) will be assessed in the brachial artery |
| Flow-volume loop assessed by spirometry | Baseline, 3 months, 6 months | Aims to investigate the mechanisms that lead to dyspnea and, consequently, intolerance to physical effort |
| Health-related quality of life assessed by the Pediatric Outcomes Data Collection Instrument | Baseline, 3 months, 6 months, 12 months | It will also be assessed for school-age children (7-10 years old) and adolescents (11-18 years old) and by their primary caregiver |
| Complete blood count (hemoglobin, leukocyte, lymphocyte and platelet count) | Baseline, 3 months, 6 months, 12 months | — |
| Inflammatory markers (C-reactive protein, fibrinogen, D-dimer and ferritin); | Baseline, 3 months, 6 months,12 months | — |
| Lactate dehydrogenase | Baseline, 3 months, 6 months, 12 months | — |
| Aspartate and alanine aminotransferase | Baseline, 3 months, 6 months, 12 months | — |
| Serum urea and creatinine | Baseline, 3 months, 6 months, 12 months | — |
| Triglycerides | Baseline, 3 months, 6 months, 12 months | — |
| Creatinine phosphokinase (CK) | Baseline, 3 months, 6 months, 12 months | — |
| Amilase | Baseline, 3 months, 6 months, 12 months | — |
| Lipase | Baseline, 3 months, 6 months, 12 months | — |
| Troponin T | Baseline, 3 months, 6 months, 12 months | — |
| Pro-BNP | Baseline, 3 months, 6 months, 12 months | — |
| Lung abnormalities will be assessed by pulmonary computed tomography | Baseline, 3 months, 6 months, 12 months | Patchy ground-glass opacities, crazy-paving pattern, and localization and pattern of large, confluent or small nodular lesions will be assessed |
| Systolic and diastolic function will be assessed by echocardiogram | Baseline, 3 months, 6 months, 12 months | Conventional transthoracic echocardiogram with color Doppler to assess systolic and diastolic function |
| Valve dysfunction will be assessed by echocardiogram | Baseline, 3 months, 6 months, 12 months | Conventional transthoracic echocardiogram with color Doppler to search for valve dysfunction |
| Pericardial effusion will be assessed by echocardiogram | Baseline, 3 months, 6 months, 12 months | Conventional transthoracic echocardiogram with color Doppler to search for pericardial effusion |
| Coronary arteries will be assessed by echocardiogram | Baseline, 3 months, 6 months, 12 months | Conventional transthoracic echocardiogram with color Doppler to search for aspects of the coronary arteries |
| Ischemia will be assessed by echocardiogram | Baseline, 3 months, 6 months, 12 months | Echocardiogram with two-dimensional speckle-tracking technique to identify subclinical changes suggestive of ischemia or myocarditis |
| Immunocompetence, including thymic function | Baseline, 3 months, 6 months, 12 months | Baseline levels of cytokines IL-2, IL-4, IL-6, IL-10, TNF-alpha, IFN-y, and IL-17A in serum samples will be tested by flow cytometry using the CBA technique (Cytometric bead array, BD Biosciences) |
| Leukogram will be assessed by leukocyte and lymphocyte counts | Baseline, 3 months, 6 months,, 12 months | — |
| Immunophenotyping of lymphocytes T cell lineages will be evaluated by flow cytometry | Baseline, 3 months, 6 months, 12 months | T cell lineages: CD3CD4, CD3CD8, naive cells (CD45RA+), memory cells (CD45RA-), effector cells (CD38+HLADR+) |
| Immunophenotyping of lymphocytes B cell lineages will be evaluated by flow cytometry | Baseline, 3 months, 6 months, 12 months | B cell lineages: CD19, naive cells (CD27-), memory cells (CD27+), plasmablasts (CD27+CD38+CD138-), (plasmocytes CD27+CD38+CD138+) |
| Immunophenotyping of lymphocytes NK cells will be evaluated by flow cytometry | Baseline, 3 months, 6 months, 12 months | NK cells: (CD3-CD16+CD56+), degranulated: CD107a+ |
| Serum levels of anti-Streptococcus pneumoniae IgG antibodies | Baseline, 3 months, 6 months, 12 months | — |
| Anti-pneumococcal vaccine response will be assessed by ELISA | Baseline, 3 months, 6 months, 12 months | The antipneumococcal antibody titer against 6 polysaccharides (serotypes 1, 5, 6B, 9V, 14, and 18C) will be analyzed by ELISA. The seroconversion criteria is IgG values \> 1.3 mg/mL for each polysaccharide assessed |
| Evaluation of the thymus by the determination of TRECs (Thymic recent emigrant cells or T-cell receptor excision circles) | Baseline, 3 months, 6 months, 12 months | TRECs evaluate the peripheral function of the thymus from cells that have recently been released, using the RT-PCR technique |
| Changes in frequency of the autoantibodies of the thyroid gland | Baseline, 3 months, 6 months, 12 months | (anti-thyroperoxidase antibodies, anti-thyroglobulin) |
| Changes in frequency of the anti-GAD antibody will be assessed using immunoprecipitation | Baseline, 3 months, 6 months, 12 months | — |
| Changes in frequency of the anti-islet antibody of Langerhans will be assessed using indirect fluorescence | Baseline, 3 months, 6 months, 12 months | — |
| Changes in frequency of the anti-insulin antibody will be assessed by radioimmunoassay | Baseline, 3 months, 6 months, 12 months | — |
| Diagnosis of thyroid dysfunction will be assessed by thyroid profile (TSH, free T4 and T3) | Baseline, 3 months, 6 months, 12 months | — |
| Diagnosis of type 1 diabetes mellitus will be assessed by the metabolic profile (fasting glucose, glycated hemoglobin and C peptide) | Baseline, 3 months, 6 months,, 12 months | — |
| Linear growth will be assessed by using a standardized stadiometer, calculating standard deviation, growth curves, and growth speed | Baseline, 3 months, 6 months, 12 months | — |
| Development of puberty will be assessed according to the criteria of Tanner and Marshall in adolescents in the prepubertal age group | Baseline, 3 months, 6 months, 12 months | — |
| Bone age will be assessed using non-dominant hand and wrist radiography | Baseline, 12 months | — |
| Bone mineral density will be assessed by Bone densitometry (DXA) in the region of the lumbar spine | Baseline, 3 months, 6 months, 12 months | — |
| Bone mineral content will be assessed by Bone densitometry (DXA) in the region of the lumbar spine | Baseline, 3 months, 6 months, 12 months | — |
| Bone mineral density will be assessed by Bone densitometry (DXA) in the proximal femur | Baseline, 3 months, 6 months, 12 months | — |
| Bone mineral content will be assessed by Bone densitometry (DXA) in the proximal femur | Baseline, 3 months, 6 months, 12 months | — |
| Bone mineral density will be assessed by Bone densitometry (DXA) in the whole body | Baseline, 3 months, 6 months, 12 months | — |
| Bone mineral content will be assessed by Bone densitometry (DXA) in the whole body | Baseline, 3 months, 6 months, 12 months | — |
| Body composition (visceral adipose tissue) will be assessed by Bone densitometry | Baseline, 3 months, 6 months, 12 months | — |
| Body composition (lean mass) will be assessed by Bone densitometry | Baseline, 3 months, 6 months, 12 months | — |
| Body composition (fat mass) will be assessed by Bone densitometry | Baseline, 3 months, 6 months, 12 months | — |
| Bone biochemical and bone remodeling markers (calcium, phosphorus, 25OH alkaline phosphatase vitamin D, PTH, CTX, P1NP) | Baseline, 3 months, 6 months, 12 months | — |
| Pediatric gait assessment will be assessed by an Actigraph (3D accelerometer) model G-Walk used during the timed up and go test | Baseline, 3 months, 6 months, 12 months | — |
| Pediatric gait assessment will be assessed by an Actigraph (3D accelerometer) model G-Walk during the 6-minute walk test | Baseline, 3 months, 6 months, 12 months | — |
| Pediatric gait assessment will be assessed by an Actigraph (3D accelerometer) model G-Walk during the 10 meter gait test | Baseline, 3 months, 6 months, 12 months | — |
| Physical activity levels assessed by ActivPAL | Baseline, 3 months, 6 months, 12 months | ActivPAL will be used for 7 days for at least 10 hours/day |
| Genetic Polymorphism Analysis will be assessed by salting out methodology followed by q-PCR (Real-time PCR) using the TaqMan assay using Step One Plus equipment | Baseline, 3 months, 6 months, 12 months | According to the gene sequence studied, the analysis will be performed using the Sanger sequencing technique with capillary electrophoresis in a 3130 automatic sequencer (Applied Biosystems). The genetic polymorphisms of the ABO system gene (rs505922), two polymorphisms of the OPRM1 gene (rs1799971 and rs1799972) and a polymorphism of the BDNF gene (rs6265) will be investigated, with possible contributions to the risk of impaired gait. |
| Food consumption levels assessed by food records | Baseline, 3 months, 6 months, 12 months | 24-hour recalls will be assessed on three non-consecutive days (two weekdays, and one weekend). Online Dietbox will be used. |
| Blood flow will be assessed using a Doppler Ultrasound | Baseline, 3 months, 6 months, 12 months | Baseline blood flow measurements will be assessed in the brachial artery |
| Mental health will be assessed by the Strengths and Weaknesses of Attention-deficit/hyperactivity disorder (ADHD) symptoms and Normal behaviors | Baseline, 3 months, 6 months, 12 months | This is an 18-item parent questionnaire for children and adolescents (18 years and younger). This rating scale includes positive weaknesses and negative strengths scoring, assessing symptoms of Attention-Deficit/Hyperactivity Disorder. Parents are asked to compare their child's behavior in a variety of settings over the past month to other children on a 7-point: 3-Far below, 2-Below, 1-Slightly below, 0-Average, -1-Slightly average, -2-Above, -3-Far above. Higher scores indicate greater symptomology |
| Mental health will be assessed by the Strengths and Difficulties Questionnaire | Baseline, 3 months, 6 months, 12 months | The Strengths and Difficulties Questionnaire (SDQ) is a brief behavioural screening questionnaire, and includes 25 items on psychological attribute: emotional symptoms (5 items), conduct problems (5 items) hyperactivity/inattention (5 items), peer relationship problems (5 items), prosocial behaviour (5 items). Higher scores indicate greater difficulties |
| Mental health will be assessed by the Depression, Anxiety and Stress Scale | Baseline, 3 months, 6 months, 12 months | The Depression, Anxiety and Stress Scale - 21 Items (DASS-21) is a set of three self-report scales designed to measure the emotional states of depression, anxiety and stress (7 items each subscale). Patients are asked to score every item on a scale from 0 (did not apply to me at all) to 3 (applied to me very much). Sum scores for the total DASS-total scale range between 0 and 120. Scores ≥60 (for DASS-total) and ≥21 (for the depression subscale) are labeled as high or severe. |
| Pediatric gait assessment will be assessed by musculoskeletal ultrasound | Baseline, 3 months, 6 months, 12 months | — |
Countries
Brazil
Outcome results
None listed